Description: Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.
Home Page: www.vaccinex.com
VCNX Technical Analysis
1895 Mount Hope Avenue
Rochester,
NY
14620
United States
Phone:
585 271 2700
Officers
| Name | Title |
|---|---|
| Dr. Maurice Zauderer Ph.D. | Co-Founder, CEO, Pres & Director |
| Mr. Scott E. Royer C.F.A., M.B.A. | Chief Financial Officer |
| Dr. Ernest S. Smith Ph.D. | Sr. VP of Research & Chief Scientific Officer |
| Dr. Elizabeth E. Evans Ph.D. | COO and Sr. VP of Discovery & Translational Medicine |
| Dr. John E. Leonard Ph.D. | Sr. VP of Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.5316 |
| Price-to-Sales TTM: | 699.3697 |
| IPO Date: | 2018-08-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 39 |